Antimicrobial resistance
(AMR) is widely acknowledged as one of
the most serious public health threats facing the world, yet the private
sector finds it challenging to generate much-needed medicines. As
an alternative discovery approach, a small array of diarylimidazoles
was screened against the ESKAPE pathogens, and the results were made
publicly available through the Open Source Antibiotics (OSA) consortium
(
). Of the 18 compounds tested (at 32 μg/mL), 15 showed >90%
growth inhibition activity against methicillin-resistant
Staphylococcus
aureus
(MRSA) alone. In the subsequent hit-to-lead optimization
of this chemotype, 147 new heterocyclic compounds containing the diarylimidazole
and other core motifs were synthesized and tested against MRSA, and
their structure–activity relationships were identified. While
potent, these compounds have moderate to high intrinsic clearance
and some associated toxicity. The best overall balance of parameters
was found with OSA_975, a compound with good potency, good solubility,
and reduced intrinsic clearance in rat hepatocytes. We have progressed
toward the knowledge of the molecular target of these phenotypically
active compounds, with proteomic techniques suggesting TGFBR1 is potentially
involved in the mechanism of action. Further development of these
compounds toward antimicrobial medicines is available to anyone under
the licensing terms of the project.